BREAKING
Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 20 minutes ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 1 hour ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 4 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 4 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 5 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 5 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 5 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 3 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 3 days ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 20 minutes ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 1 hour ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 4 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 4 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 5 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 5 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 5 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 3 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 3 days ago
ADVERTISEMENT
Market News

Vertex Pharmaceuticals Inc (VRTX): Q4 2019 Earnings Snapshot

—  Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected.  — Total revenue rose 63% to $1.41 billion, vs. $1.01 billion expected.  — For FY20, company expects total product revenues of $5.1 to $5.3 billion. — VRTX stock ended Thursday’s regular trading session down 0.9%.  Browse […]

$VRTX January 30, 2020 1 min read
Earnings Update by AlphaStreet

—  Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected. 

— Total revenue rose 63% to $1.41 billion, vs. $1.01 billion expected. 

— For FY20, company expects total product revenues of $5.1 to $5.3 billion.

— VRTX stock ended Thursday’s regular trading session down 0.9%. 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT
ADVERTISEMENT